The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease

Digestive and Liver Disease

Volumn 47, Issue 1, 2015, Pages 4-11

  Pastori, Daniele ^a   Polimeni, Licia ^b   Baratta, Francesco ^a   Pani, Arianna ^a   Del Ben, Maria ^a   Angelico, Francesco ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dyslipidaemia; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Safety; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; COMPLICATION; DYSLIPIDEMIAS; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 84919632658     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.170     Document Type: Review

References (66)

1. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology 2013, 10:686-690.
2. Pais R., Charlotte F., Fedchuk L., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology 2013, 59:550-556.
3. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology and Therapeutics 2011, 34:274-285.
4. Souza M.R., Diniz Mde F., Medeiros-Filho J.E., et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arquivos de Gastroenterologia 2012, 49:89-96.
5. Ballestri S., Lonardo A., Bonapace S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014, 20:1724-1745.
6. Oni E.T., Agatston A.S., Blaha M.J., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care. Atherosclerosis 2013, 230:258-267.
7. Del Ben M., Baratta F., Polimeni L., et al. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Internal and Emergency Medicine 2012, 7(Suppl. 3):S291-S296.
8. Stone N.J., Robinson J., Lichtenstein A.H., et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013, 63:2889-2934.
9. Patti G., Cannon C.P., Murphy S.A., et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011, 123:1622-1632.
10. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, 1:CD004816.
11. Gazzerro P., Proto M.C., Gangemi G., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacological Reviews 2012, 64:102-146.
12. Rzouq F.S., Volk M.L., Hatoum H.H., et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. American Journal of the Medical Sciences 2010, 340:89-93.
13. Bays H., Cohen D.E., Chalasani N., et al. An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology 2014, 8:S47-S57.
14. Cohen D.E., Anania F.A., Chalasani N., et al. An assessment of statin safety by hepatologists. American Journal of Cardiology 2006, 97:77C-81C.
15. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity. Alimentary Pharmacology and Therapeutics 2007, 25:1135-1151.
16. Onofrei M.D., Butler K.L., Fuke D.C., et al. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008, 28:522-529.
17. Russo M.W., Galanko J.A., Shrestha R., et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplantation 2004, 10:1018-1023.
18. Dujovne C.A. Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis". American Journal of Cardiology 2002, 89:1411-1413.
19. Alla V., Abraham J., Siddiqui J., et al. Autoimmune hepatitis triggered by statins. Journal of Clinical Gastroenterology 2006, 40:757-761.
20. Graziadei I.W., Obermoser G.E., Sepp N.T., et al. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003, 12:409-412.
21. Pelli N., Setti M., Ceppa P., et al. Autoimmune hepatitis revealed by atorvastatin. European Journal of Gastroenterology and Hepatology 2003, 15:921-924.
22. Wolters L.M., Van Buuren H.R. Rosuvastatin-associated hepatitis with autoimmune features. European Journal of Gastroenterology and Hepatology 2005, 17:589-590.
23. Bhardwaj S.S., Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clinics in Liver Disease 2007, 11:597-613. vii.
24. Jimenez-Alonso J., Osorio J.M., Gutierrez-Cabello F., et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Archives of Internal Medicine 1999, 159:1811-1812.
25. Nakad A., Bataille L., Hamoir V., et al. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999, 353:1763-1764.
26. de Castro M.L., Hermo J.A., Baz A., et al. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterologia y Hepatologia 2006, 29:21-24.
27. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). American Journal of Cardiology 1995, 76:899-905.
28. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study. American Journal of Cardiology 1995, 76:485-491.
29. Sacks F.M., Pfeffer M.A., Moye L., et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). American Journal of Cardiology 1991, 68:1436-1446.
30. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. American Journal of Cardiology 1995, 76:474-479.
31. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation 2002, 105:2341-2346.
32. de Denus S., Spinler S.A., Miller K., et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584-591.
33. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. American Journal of Cardiology 2004, 93:1473-1480.
34. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 2005, 352:1425-1435.
35. Blazing M.A., De Lemos J.A., Dyke C.K., et al. The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. American Heart Journal 2001, 142:211-217.
36. Cannon C.P., McCabe C.H., Belder R., et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. American Journal of Cardiology 2002, 89:860-861.
37. Alsheikh-Ali A.A., Maddukuri P.V., Han H., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. Journal of the American College of Cardiology 2007, 50:409-418.
38. Dale K.M., White C.M., Henyan N.N., et al. Impact of statin dosing intensity on transaminase and creatine kinase. American Journal of Medicine 2007, 120:706-712.
39. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(Suppl. 1):S1-S44. Task Force for the management of dyslipidaemias of the European Society of Cardiology and the European Atherosclerosis Society.
40. US Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Available at: http://www.fda.gov/drugs/drugsafety/ucm293101.htm.
41. Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
42. Lewis J.H., Mortensen M.E., Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453-1463.
43. Riley P., Sudarshi D., Johal M., et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. International Journal of Clinical Practice 2008, 62:374-381.
44. Han K.H., Rha S.W., Kang H.J., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). Journal of Clinical Lipidology 2012, 6:340-351.
45. Gomez-Dominguez E., Gisbert J.P., Moreno-Monteagudo J.A., et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Alimentary Pharmacology and Therapeutics 2006, 23:1643-1647.
46. Antonopoulos S., Mikros S., Mylonopoulou M., et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006, 184:233-234.
47. Abel T., Feher J., Dinya E., et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Medical Science Monitor 2009, 15:MS6-MS11.
48. Pignatelli P., Carnevale R., Pastori D., et al. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation 2012, 126:92-103.
49. Violi F., Calvieri C., Ferro D., et al. Statins as antithrombotic drugs. Circulation 2013, 127:251-257.
50. Del Ben M., Polimeni L., Carnevale R., et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 2014, 14:81.
51. Angelico F., Burattin M., Alessandri C., et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2007, CD005166.
52. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine 2010, 362:1675-1685.
53. Wang W., Zhao C., Zhou J., et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLOS ONE 2013, 8:e76538.
54. Riche D.M., Fleming J.W., Malinowski S.S., et al. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Annals of Pharmacotherapy 2014, 48:137-141.
55. Eslami L., Merat S., Malekzadeh R., et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews 2013, 12:CD008623.
56. Hyogo H., Ikegami T., Tokushige K., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatology Research 2011, 41:1057-1065.
57. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism: Clinical and Experimental 2008, 57:1711-1718.
58. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. Journal of Hepatology 2007, 47:135-141.
59. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. American Journal of Gastroenterology 2011, 106:71-77.
60. Athyros V.G., Mikhailidis D.P., Didangelos T.P., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current Medical Research and Opinion 2006, 22:873-883.
61. Nelson A., Torres D.M., Morgan A.E., et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Journal of Clinical Gastroenterology 2009, 43:990-994.
62. de Keyser C.E., Koehler E.M., Schouten J.N., et al. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. Digestive and Liver Disease 2014, 46:720-725.
63. Reiner Z. Resistance and intolerance to statins. Nutrition, Metabolism and Cardiovascular Diseases 2014, in press.
64. Weltman M.D., Farrell G.C., Hall P., et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
65. Aubert J., Begriche K., Knockaert L., et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clinics and Research in Hepatology and Gastroenterology 2011, 35:630-637.
66. Wang J., Guo X., Wu P., et al. Association between the Pro12Ala polymorphism of PPAR-gamma gene and the non-alcoholic fatty liver disease: a meta-analysis. Gene 2013, 528:328-334.